Medical Information
|
Non-US Health Care Professionals
Account Settings
Sign Out
Sign In | Create Account
  • Rare Bleeding Disorders Home
  •  Icon
    Products
    Our Treatments
    How to Order
    Trial Prescriptions
    Recombinant Manufacturing
     Icon
    Professional Resources
    Product Resources Library
    Contact Your Representative
    Medical Information
    |
    Non-US Health Care Professionals
  •  Icon
    Disease Education
    Clinical Education Library
    Congenital Hemophilia with Inhibitors
    Breakthrough Bleeds
    Acquired Hemophilia
    Glanzmann's Thrombasthenia
    Interactive Joint Bleed Model
     Icon
    Treatment Guidelines
    MASAC Guidelines
    WFH Guidelines
     Icon
    Additional Resources
    Organizations & Conferences
    Medical Information
    |
    Non-US Health Care Professionals
  •  Icon
    Product Education
    Product Education Materials
     Icon
    Disease Education
    Disease Education Resources
     Icon
    Access & Affordability
    Prescription Savings & Insurance Support
    ICD-10 Codes for Rare Bleeding Disorders
    Medical Information
    |
    Non-US Health Care Professionals
Rare Bleeding Disorders
Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei] logo
  • Why Esperoct® Pharmacology Mechanism of Action
  • Prophylaxis On Demand & Perioperative Safety Profile
  • Dosing Reconstitution & Administration
  • Cost & Coverage
  • Patient Education Education for You How to Order
Prescribing Information | Important Safety Information | Patient Site

Explore Therapeutic Areas

Diabetes Icon
Diabetes
Our broad treatment portfolio supports individualized patient care.
Obesity Icon
Obesity
Our treatments are part of a comprehensive approach to weight-loss management.
Growth-Related Disorders Icon
Growth-Related Disorders
Our products help children with a range of growth-related disorders and adults with growth hormone deficiency.
Rare Bleeding Disorders Icon
Rare Bleeding Disorders
Our commitment to patients with hemophilia and rare bleeding disorders is reflected in our broad therapy portfolio.
Rare Renal Disorders Icon
Rare Renal Disorders
Our treatment helps patients with the rare genetic disorder primary hyperoxaluria type 1 (PH1).
Medical Information
|
Non-US Health Care Professionals
  • Rare Bleeding Disorders Home
Account Settings
Sign Out
Sign In | Create Account
Update your account
Medical Information
|
Non-US Health Care Professionals

Explore the Hub

Products
Samples
Patient Savings
Contact

Explore Therapeutic Areas

Diabetes
Diabetes
Obesity
Obesity
Growth-Related Disorders
Growth-Related Disorders
Rare Bleeding Disorders
Rare Bleeding Disorders
Rare Renal Disorders
Rare Renal Disorders
Claim your personalized professional hub
What can novoMEDLINK™ do for you? With your account you can discover professional news, order samples, get supply updates, browse patient support materials, and much more.
Personalize your novoMEDLINK™ experience
Ready to further optimize your content recommendations and resource suggestions? Head to your account page to edit your settings.
Account Settings
Sign Out
Sign In | Create Account
Update your account
  • Products
    Samples
    Patient Savings
    Contact
    Diabetes
    Diabetes
    Obesity
    Obesity
    Growth-Related Disorders
    Growth-Related Disorders
    Rare Bleeding Disorders
    Rare Bleeding Disorders
    Rare Renal Disorders
    Rare Renal Disorders
Claim your personalized
professional hub
Personalize your novoMEDLINK™ experience
Account Settings
Sign Out
Sign In | Create Account
Update your account
Medical Information
|
Non-US Health Care Professionals
  • Rare Bleeding Disorders Home
  •  Icon
    Products
    Our Treatments
    How to Order
    Trial Prescriptions
    Recombinant Manufacturing
     Icon
    Professional Resources
    Product Resources Library
    Contact Your Representative
  •  Icon
    Disease Education
    Clinical Education Library
    Congenital Hemophilia with Inhibitors
    Breakthrough Bleeds
    Acquired Hemophilia
    Glanzmann's Thrombasthenia
    Interactive Joint Bleed Model
     Icon
    Treatment Guidelines
    MASAC Guidelines
    WFH Guidelines
     Icon
    Additional Resources
    Organizations & Conferences
  •  Icon
    Product Education
    Product Education Materials
     Icon
    Disease Education
    Disease Education Resources
     Icon
    Access & Affordability
    Prescription Savings & Insurance Support
    ICD-10 Codes for Rare Bleeding Disorders
Medical Information
|
Non-US Health Care Professionals

Explore Current Therapy Area

Rare Bleeding Disorders Home
Products
Our Treatments
How to Order
Trial Prescriptions
Recombinant Manufacturing
Professional Resources
Product Resources Library
Contact Your Representative
Disease Education
Clinical Education Library
Congenital Hemophilia with Inhibitors
Breakthrough Bleeds
Acquired Hemophilia
Glanzmann's Thrombasthenia
Interactive Joint Bleed Model
Treatment Guidelines
MASAC Guidelines
WFH Guidelines
Additional Resources
Organizations & Conferences
Product Education
Product Education Materials
Disease Education
Disease Education Resources
Access & Affordability
Prescription Savings & Insurance Support
ICD-10 Codes for Rare Bleeding Disorders
Diabetes
Diabetes
Obesity
Obesity
Growth-Related Disorders
Growth-Related Disorders
Rare Bleeding Disorders
Rare Bleeding Disorders
Rare Renal Disorders
Rare Renal Disorders
Medical Information
|
Non-US Health Care Professionals
Claim your personalized professional hub
What can novoMEDLINK™ do for you? With your account you can discover professional news, order samples, get supply updates, browse patient support materials, and much more.
Personalize your novoMEDLINK™ experience
Ready to further optimize your content recommendations and resource suggestions? Head to your account page to edit your settings.
Account Settings
Sign Out
Sign In | Create Account
Update your account

Explore Current Therapy Area

  • Rare Bleeding Disorders Home
  •  Icon
    Products
    Our Treatments
    How to Order
    Trial Prescriptions
    Recombinant Manufacturing
     Icon
    Professional Resources
    Product Resources Library
    Contact Your Representative
  •  Icon
    Disease Education
    Clinical Education Library
    Congenital Hemophilia with Inhibitors
    Breakthrough Bleeds
    Acquired Hemophilia
    Glanzmann's Thrombasthenia
    Interactive Joint Bleed Model
     Icon
    Treatment Guidelines
    MASAC Guidelines
    WFH Guidelines
     Icon
    Additional Resources
    Organizations & Conferences
  •  Icon
    Product Education
    Product Education Materials
     Icon
    Disease Education
    Disease Education Resources
     Icon
    Access & Affordability
    Prescription Savings & Insurance Support
    ICD-10 Codes for Rare Bleeding Disorders
  • Diabetes
    Diabetes
    Obesity
    Obesity
    Growth-Related Disorders
    Growth-Related Disorders
    Rare Bleeding Disorders
    Rare Bleeding Disorders
    Rare Renal Disorders
    Rare Renal Disorders

Claim your personalized
professional hub

Personalize your novoMEDLINK™ experience

Account Settings
Sign Out
Sign In | Create Account
Update your account
Medical Information
|
Non-US Health Care Professionals
  • Why Esperoct®
    Pharmacology
    Mechanism of Action
  • Prophylaxis
    On Demand & Perioperative
    Safety Profile
  • Dosing
    Reconstitution & Administration
  • Cost & Coverage
  • Patient Education
    Education for You
    How to Order
Prescribing Information | Important Safety Information | Patient Site
Medical Information
|
Non-US Health Care Professionals
 |  Important Safety Information

NovoSeven® RT (coagulation Factor VIIa, recombinant)

Alhemo® (concizumab-mtci) injection 60 mg, 150 mg, 300 mg pens

Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei]

Novoeight® (antihemophilic factor, recombinant)

Rebinyn® coagulation factor IX (recombinant), glycoPEGylated

Tretten® (coagulation factor XIII A-subunit [recombinant])

    • Why Esperoct®
    • Pharmacology
    • Mechanism of Action
    • Prophylaxis
    • On Demand & Perioperative
    • Safety Profile
    • Dosing
    • Reconstitution & Administration
  • Cost & Coverage
    • Patient Education
    • Education for You
    • How to Order

Indicated for use in adults and children with hemophilia A for on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequency of bleeding episodes. Esperoct® is not indicated for the treatment of von Willebrand disease.

Talk to us about Esperoct®.

Bleed protection across all ages1,2

In open-label clinical trials, Esperoct® achieved a longer half-life across age groups when compared to standard half-life (SHL) Factor VIII products.3,4

Esperoct® vial
Esperoct® vial

Longer half-life compared to SHL FVIII products3,4

In patients ≥18 years of age

In pathfinder1, a phase 1 study with adult patients, Esperoct® achieved a 60% longer half-life compared to SHL FVIII products.3

See study design
Half-life graph legend
Half-life graph

Keep them covered longer

Esperoct® achieved a 22-hour half-life in adults.5,a

22-hour icon

in adults with site-directed glycoPEGylation4


aIn a phase 3, open-label study, safety, efficacy, and pharmacokinetics (PK) of Esperoct® were evaluated in previously treated patients (PTPs) aged ≥12 years with severe hemophilia A. Single-dose PK studies were performed in 42 adults after receiving Esperoct® 50 IU/kg (includes adult patients from pathfinder2 Phase 3 trial and Phase 1 PK trials).5,6

In patients <12 years of age

In pathfinder5, a phase 3 open-label study with pediatric previously treated patients, Esperoct® achieved an 85% longer half-life compared to SHL FVIII products.4

See study design
85% icon

Compared with SHL FVIII products

Toy castle

Keep them covered longer

In pathfinder5, a phase 3 study of children (aged <12 years), Esperoct® achieved a 14.3-hour mean half-life.4,b

See study design
14.3-hour icon

mean half-life in children4,b


bFor children aged 6-11 years.

Achieve high trough levels for a broad range of patients

The pharmacokinetics (PK) of Esperoct® were evaluated in previously treated patients with severe hemophilia A. Esperoct® achieved high factor levels in adolescents, adults, and children.5,c

cFor children aged 6-11 years, trough level is 2%.

In patients aged 12 to 70 years

In patients aged 0 to <12 years

Pivotal trial main phase

In the pathfinder2 open-label study, Esperoct® achieved factor levels ≥3% for the entire dosing interval and in PK modeling data ≥5% for 90% of the time.5

3% icon
See study design
5% icon

6+ years post hoc analysis

In a post hoc analysis, long-term prophylaxis (≥6 years) showed a stabilization in mean FVIII trough levels and decrease in annualized bleed rate over time.7,g

5% mean icon

In patients aged 0 to <12 years

Pivotal trial main phase

In the pathfinder5 open-label study, Esperoct® achieved factor levels ≥2% for the entire dosing interval for children aged 6 to 11 years, and in PK modeling data, ≥5% for 72% of the dosing interval for children aged 0 to <12 years.5

Aged 6-11 years

2% icon
See study design

Aged 0 to <12 years

5% icon

5+ years post hoc analysis

In a post hoc analysis, long-term prophylaxis (≥5 years) showed a stabilization in mean FVIII trough levels.7,h

4% mean icon

dMean trough levels for adolescents (aged 12-<18 years) were 2.7 IU/dL.

eSteady-state FVIII activity profiles were estimated in 143 patients using a one-compartment model with first-order elimination with PK parameters of clearance and volume of distribution.5

fSteady-state FVIII activity profiles were estimated in 22 children using a one-compartment model with first-order elimination, including PK parameters of clearance and volume of distribution.5

gPost hoc analyses were performed on data from the pathfinder2 trial of patients aged ≥12 years with severe hemophilia A who received prophylaxis Q4D. Exploratory descriptive analyses of the data were used to evaluate long-term annual bleed rates and mean factor VIII trough levels which were assessed over time in 53 patients who received ≥6 years of prophylaxis, every 4 days. Limitations of the analyses include the lack of baseline joint status data, which is clinically relevant for phenotypic assessment prior to treatment initiation. The absence limits the ability to draw conclusions regarding improvement in joint status over time. Several trough-level data were excluded if it was believed that they were elevated due to dosing to treat a recent bleed.7

hPost hoc analyses were performed on data from the pathfinder5 trial of patients (aged <12 years) with severe hemophilia A. Exploratory descriptive analyses of the data were used to evaluate mean factor VIII trough levels which were assessed over time in 54 patients who received ≥5 years of twice-weekly prophylaxis. Limitations of the analyses include the exclusion of several trough-level data if believed that they were elevated due to dosing to treat a recent bleed.7

Study designs

Tiede et al (2013)3
pathfinder1 phase 1 clinical trial

Patients: Previously treated males aged ≥18 years (n=26) with severe hemophilia A, a residual FVIII activity of <1%, and at least 150 days of exposure to an FVIII product.

Study design: Open-label dose-escalation trial. Patients received a single dose of 25, 50, or 75 IU/kg of their previous SHL product (pdFVIII or rFVIII), followed by the same dose of Esperoct® after a minimum 4-day wash-out period. To allow for comparison, all results were adjusted to a 50 IU/kg dose of each product.3

Primary endpoint: Evaluating adverse events and antibody formation, including inhibitors against FVIII and Esperoct®, and binding antibodies against Esperoct®.

Secondary endpoints: Evaluating the PK profile of Esperoct® and comparing Esperoct® FVIII activity with that of the patients’ previous FVIII products.3

Giangrande et al (2017 and 2020)1,6
pathfinder2 phase 3 clinical trial: main phase and extension

Patients: Previously treated males aged 12–66 years with severe congenital hemophilia A (FVIII activity <1%) and at least 150 exposure days to any FVIII products.6

Study design: Multinational, open-label, non-randomized trial evaluating safety, pharmacokinetics, and clinical efficacy of Esperoct® when used for prophylaxis and treatment of bleeds. During the main phase, 175 patients received routine prophylaxis (50 IU/kg every 4 days), and 12 adults elected to be treated on-demand. A subset of patients (n=150) continued on in extension phase part 1; 139 continued into the non-randomized extension part 2, with 113 completing the trial.1,6

Co-primary endpoints: Incidence of FVIII inhibitors ≥0.6 BU (Bethesda units) and ABR (annualized bleeding rate) for patients on prophylaxis.6

Meunier et al (2017)4
pathfinder5 phase 3 clinical trial

Patients: Previously treated males (n=68) aged <12 years with severe hemophilia A (FVIII activity level of <1%) and a body weight ≥10 kg. Patients aged 0–5 years had at least 50 exposure days to other FVIII products. Patients aged 6–11 years had at least 150 exposure days.

Study design: Multinational, open-label, non-randomized, non-controlled trial evaluating the safety, clinical efficacy, and pharmacokinetics of prophylactic and treatment on demand of Esperoct®. For bleeding episodes, treatment dose was 20–75 IU/kg, depending on bleed severity and location. For prophylaxis, patients administered 60 IU/kg (50–75 IU/kg) twice weekly for 26 weeks.

Prior to the start of routine prophylaxis, single-dose PK comparison was performed in 27 children between previous SHL products and Esperoct® at the same administered dose. Half-life comparison is based on estimated terminal half-life ratio using a population-based method.

Primary endpoint: Incidence of inhibitory antibodies against FVIII, indicated by a result of ≥0.6 BU (Bethesda units), as measured with the Nijmegen-modified Bethesda assay with heat inactivation of residual FVIII activity.

Secondary endpoint: Frequency of adverse events, including serious adverse effects, inhibitor formation against FVIII, allergic reactions, thromboembolic events, and medication errors.

One proven starting dose for routine prophylaxis (adults and adolescents)

50 IU/kg
  • No dose adjustment needed or related PK testing required5,6
  • Regimen can be individualized to less or more frequent dosing based on bleeding episodes5
Review our dosing

PEGylation technology

Esperoct® mechanism of action illustration

Esperoct® extends half-life through PEGylation.3,5

See how it works
Show More Show Less

Important Safety Information for Esperoct®

Contraindications

  • Do not use in patients who have known hypersensitivity to Esperoct® or its components, including hamster proteins

Warnings and Precautions

  • Hypersensitivity reactions, including anaphylaxis, may occur. Should hypersensitivity reactions occur, discontinue Esperoct® and administer appropriate treatment
  • Development of neutralizing antibodies (inhibitors) has occurred. Perform an assay that measures Factor VIII inhibitor concentration if bleeding is not controlled with the recommended dose of Esperoct® or if the expected plasma Factor VIII activity levels are not attained
  • Temporary decrease in Factor VIII incremental recovery (IR) has been observed after Esperoct® infusion, within the first 5 exposure days, in previously untreated patients (PUPs) <6 years of age. During the decreased IR period, these subjects may have an increased bleeding tendency. If bleeding is not controlled with the recommended dose of Esperoct® and/or the expected Factor VIII activity levels are not attained and Factor VIII inhibitors are not detected, consider adjusting the dose, dosing frequency, or discontinuing Esperoct®

Adverse Reactions

  • The most frequently reported adverse reactions in clinical trials (≥1%) were rash, redness, itching (pruritus), and injection site reactions. Additional frequently reported adverse reactions (≥1%) in PUPs included Factor VIII inhibition and hypersensitivity.

Please click here for Esperoct® Prescribing Information.

Indications and Usage

Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei] is indicated for use in adults and children with hemophilia A for on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequency of bleeding episodes

  • Esperoct® is not indicated for the treatment of von Willebrand disease

Indications and Usage

Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei] is indicated for use in adults and children with hemophilia A for on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequency of bleeding episodes

  • Esperoct® is not indicated for the treatment of von Willebrand disease

Important Safety Information for Esperoct®

Contraindications

  • Do not use in patients who have known hypersensitivity to Esperoct® or its components, including hamster proteins

Warnings and Precautions

  • Hypersensitivity reactions, including anaphylaxis, may occur. Should hypersensitivity reactions occur, discontinue Esperoct® and administer appropriate treatment
  • Development of neutralizing antibodies (inhibitors) has occurred. Perform an assay that measures Factor VIII inhibitor concentration if bleeding is not controlled with the recommended dose of Esperoct® or if the expected plasma Factor VIII activity levels are not attained
  • Temporary decrease in Factor VIII incremental recovery (IR) has been observed after Esperoct® infusion, within the first 5 exposure days, in previously untreated patients (PUPs) <6 years of age. During the decreased IR period, these subjects may have an increased bleeding tendency. If bleeding is not controlled with the recommended dose of Esperoct® and/or the expected Factor VIII activity levels are not attained and Factor VIII inhibitors are not detected, consider adjusting the dose, dosing frequency, or discontinuing Esperoct®

Adverse Reactions

  • The most frequently reported adverse reactions in clinical trials (≥1%) were rash, redness, itching (pruritus), and injection site reactions. Additional frequently reported adverse reactions (≥1%) in PUPs included Factor VIII inhibition and hypersensitivity.

Please click here for Esperoct® Prescribing Information.

Show More Show Less
Show More Show Less

Indications and Usage

Indications and Usage

Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei] is indicated for use in adults and children with hemophilia A for on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequency of bleeding episodes

  • Esperoct® is not indicated for the treatment of von Willebrand disease

Important Safety Information for Esperoct®

Contraindications

  • Do not use in patients who have known hypersensitivity to Esperoct® or its components, including hamster proteins

Important Safety Information for Esperoct®

Contraindications

  • Do not use in patients who have known hypersensitivity to Esperoct® or its components, including hamster proteins

Warnings and Precautions

  • Hypersensitivity reactions, including anaphylaxis, may occur. Should hypersensitivity reactions occur, discontinue Esperoct® and administer appropriate treatment
  • Development of neutralizing antibodies (inhibitors) has occurred. Perform an assay that measures Factor VIII inhibitor concentration if bleeding is not controlled with the recommended dose of Esperoct® or if the expected plasma Factor VIII activity levels are not attained
  • Temporary decrease in Factor VIII incremental recovery (IR) has been observed after Esperoct® infusion, within the first 5 exposure days, in previously untreated patients (PUPs) <6 years of age. During the decreased IR period, these subjects may have an increased bleeding tendency. If bleeding is not controlled with the recommended dose of Esperoct® and/or the expected Factor VIII activity levels are not attained and Factor VIII inhibitors are not detected, consider adjusting the dose, dosing frequency, or discontinuing Esperoct®

Adverse Reactions

  • The most frequently reported adverse reactions in clinical trials (≥1%) were rash, redness, itching (pruritus), and injection site reactions. Additional frequently reported adverse reactions (≥1%) in PUPs included Factor VIII inhibition and hypersensitivity.

Please click here for Esperoct® Prescribing Information.

Important Safety Information for Esperoct®

Contraindications

  • Do not use in patients who have known hypersensitivity to Esperoct® or its components, including hamster proteins

Warnings and Precautions

  • Hypersensitivity reactions, including anaphylaxis, may occur. Should hypersensitivity reactions occur, discontinue Esperoct® and administer appropriate treatment
  • Development of neutralizing antibodies (inhibitors) has occurred. Perform an assay that measures Factor VIII inhibitor concentration if bleeding is not controlled with the recommended dose of Esperoct® or if the expected plasma Factor VIII activity levels are not attained
  • Temporary decrease in Factor VIII incremental recovery (IR) has been observed after Esperoct® infusion, within the first 5 exposure days, in previously untreated patients (PUPs) <6 years of age. During the decreased IR period, these subjects may have an increased bleeding tendency. If bleeding is not controlled with the recommended dose of Esperoct® and/or the expected Factor VIII activity levels are not attained and Factor VIII inhibitors are not detected, consider adjusting the dose, dosing frequency, or discontinuing Esperoct®

Adverse Reactions

  • The most frequently reported adverse reactions in clinical trials (≥1%) were rash, redness, itching (pruritus), and injection site reactions. Additional frequently reported adverse reactions (≥1%) in PUPs included Factor VIII inhibition and hypersensitivity.

Please click here for Esperoct® Prescribing Information.

Indications and Usage

Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei] is indicated for use in adults and children with hemophilia A for on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequency of bleeding episodes

  • Esperoct® is not indicated for the treatment of von Willebrand disease

Indications and Usage

Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei] is indicated for use in adults and children with hemophilia A for on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequency of bleeding episodes

  • Esperoct® is not indicated for the treatment of von Willebrand disease

Important Safety Information for Esperoct®

Contraindications

  • Do not use in patients who have known hypersensitivity to Esperoct® or its components, including hamster proteins

Warnings and Precautions

  • Hypersensitivity reactions, including anaphylaxis, may occur. Should hypersensitivity reactions occur, discontinue Esperoct® and administer appropriate treatment
  • Development of neutralizing antibodies (inhibitors) has occurred. Perform an assay that measures Factor VIII inhibitor concentration if bleeding is not controlled with the recommended dose of Esperoct® or if the expected plasma Factor VIII activity levels are not attained
  • Temporary decrease in Factor VIII incremental recovery (IR) has been observed after Esperoct® infusion, within the first 5 exposure days, in previously untreated patients (PUPs) <6 years of age. During the decreased IR period, these subjects may have an increased bleeding tendency. If bleeding is not controlled with the recommended dose of Esperoct® and/or the expected Factor VIII activity levels are not attained and Factor VIII inhibitors are not detected, consider adjusting the dose, dosing frequency, or discontinuing Esperoct®

Adverse Reactions

  • The most frequently reported adverse reactions in clinical trials (≥1%) were rash, redness, itching (pruritus), and injection site reactions. Additional frequently reported adverse reactions (≥1%) in PUPs included Factor VIII inhibition and hypersensitivity.

Please click here for Esperoct® Prescribing Information.

References:
  1. Giangrande P, Karim F, Nemes L, et al. Long-term safety and efficacy of N8-GP in previously treated adults and adolescents with hemophilia A: final results from pathfinder2. J Thromb Haemost. 2020;18(1):5-14.
  2. Šaulytė Trakymiene S, Economou M, Kenet G, Landorph A, Shen C, Kearney S. Long-term safety and efficacy of N8-GP in previously treated pediatric patients with hemophilia A: final results from pathfinder5. J Thromb Haemost. 2020;18(suppl 1):15-25.
  3. Tiede A, Brand B, Fischer R, et al. Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A. J Thromb Haemost. 2013;11(4):670-678. 
  4. Meunier S, Alamelu J, Ehrenforth S, et al. Safety and efficacy of a glycoPEGylated rFVIII (turoctocog alpha pegol, N8-GP) in paediatric patients with severe haemophilia A. Thromb Haemost. 2017;117:1705-1713.
  5. Esperoct® [package insert]. Plainsboro, NJ: Novo Nordisk Inc.
  6. Giangrande P, Andreeva T, Chowdary P, et al. Clinical evaluation of glycoPEGylated recombinant FVIII: efficacy and safety in severe haemophilia A. Thromb Haemost. 2017;117(2):252-261.
  7. Tiede A, Hampton K, Jimenez-Yuste V, Young G, Benchikh El Fegoun S, Chowdry P. Post-hoc analysis on the long-term response to fixed-dose prophylaxis with N8-GP in patients with haemophilia A. Haemophilia. 2021;10.1111/hae.14409.
For Health Care Professionals
  • Rare Bleeding Disorders Home
  • Product Information
    Products
    • Our Treatments
      How to Order
      Trial Prescriptions
      Recombinant Manufacturing
    Professional Resources
    • Product Resources Library
      Contact Your Representative
  • Professional Education
    Disease Education
    • Clinical Education Library
      Congenital Hemophilia with Inhibitors
      Breakthrough Bleeds
      Acquired Hemophilia
      Glanzmann's Thrombasthenia
      Interactive Joint Bleed Model
    Treatment Guidelines
    • MASAC Guidelines
      WFH Guidelines
    Additional Resources
    • Organizations & Conferences
  • Patient Support
    Product Education
    • Product Education Materials
    Disease Education
    • Disease Education Resources
    Access & Affordability
    • Prescription Savings & Insurance Support
      ICD-10 Codes for Rare Bleeding Disorders

Esperoct® is a registered trademark of Novo Nordisk Health Care AG.
novoMEDLINK™ is a trademark of Novo Nordisk A/S.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
All other trademarks, registered or unregistered, are the property of their respective owners.
Non-US Health Care Professionals, please go to www.novonordiskpro.com.

Terms of Use | Privacy Notice | Consumer Health Privacy Notice | Cookie Notice | Privacy Request | Contact Us |
novonordisk-us.com    
© 2024 Novo Nordisk All rights reserved. US24ESP00008 August 2024

What can we help you do today?

Quick links

Trial prescription programs

Patient access and affordability options

MASAC treatment guidelines

Patient educational materials

Medical Information     |     Non-US Health Care Professionals